New drug trial aims to boost blood counts, cut transfusions for MDS patients
NCT ID NCT06304103
Summary
This study is testing an investigational oral drug called AND017 for people with lower-risk myelodysplastic syndromes (MDS) who have anemia. The main goal is to see if the drug can safely increase hemoglobin levels (a measure of red blood cells) and reduce the need for blood transfusions. About 63 participants will receive different doses to find the most effective and safe amount.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Affiliated Hospital of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 30003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.